CL2011002664A1 - Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. - Google Patents

Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.

Info

Publication number
CL2011002664A1
CL2011002664A1 CL2011002664A CL2011002664A CL2011002664A1 CL 2011002664 A1 CL2011002664 A1 CL 2011002664A1 CL 2011002664 A CL2011002664 A CL 2011002664A CL 2011002664 A CL2011002664 A CL 2011002664A CL 2011002664 A1 CL2011002664 A1 CL 2011002664A1
Authority
CL
Chile
Prior art keywords
vector
nucleic acid
procedure
cxcr4
study
Prior art date
Application number
CL2011002664A
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41060014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002664(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CL2011002664A1 publication Critical patent/CL2011002664A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CL2011002664A 2009-04-29 2011-10-26 Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. CL2011002664A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17368009P 2009-04-29 2009-04-29
EP09159076A EP2246364A1 (en) 2009-04-29 2009-04-29 Anti CXCR4 antibodies for the treatment of HIV

Publications (1)

Publication Number Publication Date
CL2011002664A1 true CL2011002664A1 (es) 2012-12-14

Family

ID=41060014

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002664A CL2011002664A1 (es) 2009-04-29 2011-10-26 Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.

Country Status (25)

Country Link
US (3) US9090686B2 (es)
EP (2) EP2246364A1 (es)
JP (1) JP5800802B2 (es)
KR (1) KR20120039525A (es)
CN (1) CN102459343B (es)
AU (1) AU2010243526B2 (es)
BR (2) BRPI1011540A2 (es)
CA (1) CA2759989A1 (es)
CL (1) CL2011002664A1 (es)
CO (1) CO6390114A2 (es)
ES (1) ES2534313T3 (es)
GE (1) GEP20146181B (es)
HU (1) HUE025083T2 (es)
IL (1) IL215919A0 (es)
MA (1) MA33285B1 (es)
MX (1) MX2011011285A (es)
MY (1) MY155400A (es)
NZ (1) NZ596712A (es)
PL (1) PL2424897T3 (es)
RU (1) RU2573902C2 (es)
SG (1) SG175353A1 (es)
TN (1) TN2011000534A1 (es)
UA (1) UA107929C2 (es)
WO (1) WO2010125162A1 (es)
ZA (1) ZA201108330B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055980A1 (en) * 2010-10-27 2012-05-03 Pierre Fabre Medicament Antibodies for the treatment of hiv
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
CA2858350A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
AU2014360760B2 (en) 2013-12-02 2019-12-12 The Trustees Of Columbia University In The City Of New York Improved HIV-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
PL3390441T3 (pl) 2015-12-15 2022-01-10 Gilead Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
US11180575B2 (en) 2018-12-28 2021-11-23 Corn Products Development, Inc. Thermally inhibited starch and process for making
KR102825164B1 (ko) 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
CN111214650A (zh) * 2018-11-23 2020-06-02 广州溯原生物科技有限公司 一种hiv抗原-受体三聚体复合物的解离因子的应用
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
JP7645198B2 (ja) 2019-05-23 2025-03-13 ブリストル－マイヤーズ スクイブ カンパニー 細胞培養培地をモニターする方法
EP4090433A4 (en) * 2020-01-16 2024-02-14 Caerus Therapeutics, Inc. HUMANIZED ANTIBODIES SPECIFIC FOR MYELOMA AND OVARIAL CARCINOMA CELLS
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
US12006353B2 (en) * 2022-07-25 2024-06-11 Long Chen Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof
CN115724993A (zh) * 2022-07-26 2023-03-03 陈龙 Scfv蛋白的应用、car基因表达载体、car-t细胞及应用
TW202430550A (zh) 2022-10-18 2024-08-01 日商明治製菓藥業股份有限公司 Ｔ細胞性腫瘤之治療劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
AU662891B2 (en) * 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0672068A4 (en) * 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
EP0854918A1 (en) * 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
US20030049251A1 (en) * 1999-12-08 2003-03-13 Barbas Carlos F. Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP2007528711A (ja) * 2003-06-30 2007-10-18 バイオ−テクノロジー・ジェネラル（イスラエル）リミテッド 抗体及びその使用
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CA2664752A1 (en) * 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Antibodies against ccr5 and uses thereof
US8192740B2 (en) * 2007-02-27 2012-06-05 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
EA201071300A1 (ru) * 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
AU2010318542B2 (en) * 2009-10-29 2015-08-27 Janssen Biotech Inc. Antibody glycosylation variants
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
RU2573902C2 (ru) 2016-01-27
WO2010125162A1 (en) 2010-11-04
ZA201108330B (en) 2012-09-26
NZ596712A (en) 2013-10-25
MA33285B1 (fr) 2012-05-02
GEP20146181B (en) 2014-10-27
UA107929C2 (en) 2015-03-10
JP2012525129A (ja) 2012-10-22
BRPI1011540A2 (pt) 2019-04-30
US20130174288A1 (en) 2013-07-04
EP2424897B1 (en) 2015-01-07
EP2246364A1 (en) 2010-11-03
US20110088104A1 (en) 2011-04-14
CN102459343B (zh) 2015-09-16
HUE025083T2 (en) 2016-02-29
RU2011148077A (ru) 2013-06-10
KR20120039525A (ko) 2012-04-25
TN2011000534A1 (en) 2013-05-24
HK1165813A1 (en) 2012-10-12
BR112013009984A2 (pt) 2017-07-18
CO6390114A2 (es) 2012-02-29
ES2534313T3 (es) 2015-04-21
SG175353A1 (en) 2011-11-28
MY155400A (en) 2015-10-15
CA2759989A1 (en) 2010-11-04
JP5800802B2 (ja) 2015-10-28
US9090686B2 (en) 2015-07-28
AU2010243526A1 (en) 2011-12-22
CN102459343A (zh) 2012-05-16
PL2424897T3 (pl) 2015-07-31
EP2424897A1 (en) 2012-03-07
AU2010243526B2 (en) 2015-02-12
US20160031995A1 (en) 2016-02-04
IL215919A0 (en) 2011-12-29
MX2011011285A (es) 2012-01-20

Similar Documents

Publication Publication Date Title
CL2013002044A1 (es) Anticuerpo que une il-17a humano e il-17f humano; secuencia de adn que lo codifica; vector; celula huesped; proceso de produccion; composicion farmaceutica que lo comprende; y su uso para el tratamiento profilaxis de un trastorno patologico mediado por il-17a y/o il-17f.
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
CL2013000868A1 (es) Anticuerpo aislado que se une al complejo i del citomegalovirus humano (hcmv) o al gh de hcmv; acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para tratar, inhibir o prevenir la infeccion por hcmv.
CL2015000665A1 (es) Compuesto análogo de glucagón útil para prevenir ganancia de peso o promover pérdida de peso; ácido nucleico que lo codifica; vector; célula huésped; kit; y procedimiento de producción.
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
CL2011002003A1 (es) Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer.
CL2013000545A1 (es) Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune.
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2013001121A1 (es) Acido ribonucleico interferente; polinucleotido que lo codifica; construccion de adn que lo codifica; celula huesped; composicion que lo comprende; y su uso para la prevencion y/o control de la infestacion por plaga.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
MX386750B (es) MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.
CL2008000820A1 (es) Anticuerpo aislado o fragmentos funcionales con capacidad para neutralizar cepas hiv; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir un anticuerpo; uso del anticuerpo para el tratamie
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112015010817A2 (pt) anticorpos anti-hemaglutinina, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
MX2016002166A (es) Anticuerpos.
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62